- Home
- MEIP vs XTLB Comparison
MEIP vs XTLB Comparison
Compare MEIP & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- XTLB
- Stock Information
- Founded
- MEIP 2000
- XTLB 1993
- Country
- MEIP United States
- XTLB Israel
- Employees
- MEIP N/A
- XTLB N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- MEIP Health Care
- XTLB Health Care
- Exchange
- MEIP Nasdaq
- XTLB Nasdaq
- Market Cap
- MEIP 16.3M
- XTLB 16.3M
- IPO Year
- MEIP 2003
- XTLB 2005
- Fundamental
- Price
- MEIP $2.87
- XTLB $1.66
- Analyst Decision
- MEIP Hold
- XTLB
- Analyst Count
- MEIP 2
- XTLB 0
- Target Price
- MEIP $7.00
- XTLB N/A
- AVG Volume (30 Days)
- MEIP 36.2K
- XTLB 14.5K
- Earning Date
- MEIP 02-11-2025
- XTLB 02-21-2025
- Dividend Yield
- MEIP N/A
- XTLB N/A
- EPS Growth
- MEIP N/A
- XTLB N/A
- EPS
- MEIP N/A
- XTLB N/A
- Revenue
- MEIP N/A
- XTLB $46,000.00
- Revenue This Year
- MEIP N/A
- XTLB N/A
- Revenue Next Year
- MEIP $300.00
- XTLB N/A
- P/E Ratio
- MEIP N/A
- XTLB N/A
- Revenue Growth
- MEIP 33.76
- XTLB N/A
- 52 Week Low
- MEIP $2.30
- XTLB $0.77
- 52 Week High
- MEIP $4.97
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- MEIP 66.22
- XTLB 40.75
- Support Level
- MEIP $2.56
- XTLB $1.62
- Resistance Level
- MEIP $2.78
- XTLB $1.85
- Average True Range (ATR)
- MEIP 0.15
- XTLB 0.23
- MACD
- MEIP 0.04
- XTLB -0.03
- Stochastic Oscillator
- MEIP 100.00
- XTLB 18.18
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.